Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
64 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT02069704 | Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients | completed | Phase 1 | 142 | mAbxience Research S.L.INDUSTRY | 5 | Jul 23, 2019 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT01355302 | E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer | terminated | Phase 1 / Phase 2 | 7 | Eisai Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT03113747 | Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs)(ADSCs-BWs) | unknown | Phase 1 / Phase 2 | 20 | A.A. Partners, LLCOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01585649 | PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma | completed | Phase 1 | 21 | Merckle GmbHINDUSTRY | 6 | May 18, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT00768755 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 180 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00364754 | Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer | completed | Phase 1 | 28 | YM BioSciencesINDUSTRY | 3 | Apr 21, 2014 | clinicaltrials |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | completed | Phase 1 | 186 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Oct 22, 2013 | clinicaltrials |
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 24, 2010 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials